Subject Index For Volume 42

Acetate dialysis (abst) 233, 806Acetate-free bicarbonate dialysate (abst) 237Acetate-free biofiltration (abst) 218, 230, 233, 501Acid-base balance

ion H unit scale (abst) 236pH changes, uremic neutrophils 690relationship of EPO (abst) 804

Acquired cystic renal disease (abst) 198Actin, PDGF in glomerulogenesis 390Acute arterial occlusion in ARF (abst) 215Acute pancreatitis, CAPD (abst) 1287Acute pyelonephritis (abst) 1040, 1043Acute renal failure

acute arterial occlusion (abst) 215insulin-like growth factor-I (abst) 1048ischemic, urodilatin, dopamine 1153mild renal ischemia 610nephrotic syndrome (abst) 495percutaneous biopsy (abst) 495thrombocytopenia (abst) 1044

Acyclovir, cytomegalovirus, allografts (abst) 235Adenosine triphosphatase in medulla 1093Adenylate cyclase activity, cytokines 559ADP, mitochondria-transport ATPases (abst) 221

Adrenalectomy, lipocortin-l mRNA (abst) 800Adriamycin

blunted volume expansion natriuresis (abst) 234glomerulosclerosis, captopril (abst) 506nephropathy (abst) 1283nephrotic syndrome, antioxidants (abst) 507

Alanine cytoprotective action 775Albumin

excretion, children (abst) 1044excretion, glycosaminoglycans 285GBM permeability 25

Alcoholism, GN, post-infectious (abst) 232Aldosterone, target epithelia 250Alfacalcidol, hyperparathyroidism (abst) 1035Allografts.

acyclovir, cytomegalovirus (abst) 235dysfunction, cytomegalovirus (abst) 222dysfunction, Doppler (abst) 221}ILA sensitization (abst) 220IL-2, TNF, neopterine, creatinine (abst) 231rejection, immunopharmacology 38:S-182rejection, T-cells (abst) 1047renal artery stenosis, transplantation (abst) 1286survival rates (abst) 220

Alport syndromeCOL4A5 deletion 1336COL4A5 mutations 83COL4A5 structure, diffuse leiomyomatosis 1178collagen IV, GBM 179collagen IV, V and VI 115

Aluminumblood levels, hemoglobin (abst) 502blood levels (abst) 204bone disease, predialysis (abst) 212

bone disease, RF (abst) 213renal osteodystrophy (abst) 498

Aluminum toxicitycalcium alginate, HD (abst) 1045

prurigo nodularis (abst) 1044

Amiloride, lithium reabsorption (abst) 1286

Ammonia, protein metabolism 595Amylase isoenzymes, renal clearance (abst) 1286

Amyloidosisdialysis-related 38:S-78dialysis-related, protease inhibitors 915dialysis-related, systemic (abst) 201HD membrane, a-2M (abst) 1040

Analgesic nephropathy (abst) 1044Anaphylactoid reactions

hemodialysis (abst) 218reused dialyzers 1232

Anemiahemodialysis, angiodysplasia (abst) 228hemodialysis, rHuEPO (abst) 501

multiple myeloma, ESRD (abst) 233pathogenesis in CRF (abst) 796predialysis CRF, rHuEPO (abst) 498transplantation, enalapril (abst) 206

transplantation, EPO-deficiency (abst) 216uremia, EPO 975uremia, EPO, hypoxic vasodilation 975uremia, rHuEPO 38:S-142

Angiodysplasia, HD, anemia (abst) 228Angiotensin, blood pressure, CRF 46Angiotensin converting enzyme (ACE) inhibition

BP control (abst) 220bradykinin, Nephrology Forum 1020calcium antagonists, renal mass, BP (abst) 211decrease in proteinuria (abst) 1285EPO concentrations (abst) 1030hypoxemia-induced insufficiency (abst) 799metabolic effects (abst) 1039microalbuminuria (abst) 200nephrotic proteinuria (abst) 213renal disease, Nephrology Forum 463

Angiotensin IIendothelin secretion, MC 860receptors in rat medulla 1372stenotic kidney 417

Anisodamine, ARF (abst) 495Anti-DNA antibodies, glomerular binding 1363Anti-endothelial cell antibodies, SLE (abst) 1038Anti-GBM glomerulonephritis

deoxyspergualin therapy (abst) 1034glomerular fibrinolytic activity (abst) 1034T-cells (abst) 1032

Anti-hypertensive drugs, renal effect 354Anticardiolipin antibodies (abst) 233Antilymphocyte globulins, transplantation 38:S- 188Antioxidants, adriamycin, nephrotic syndrome (abst).... 507

1522

brought to you by COREView metadata, citation and similar papers at core.ac.uk

provided by Elsevier - Publisher Connector

Subject Index: Vol. 42 1523

Antiphospholipid antibodiesglomerulopathy (abst) 225HD,CRF(abst) 211

Aortocaval fistula, ANP, in dogs 867Arginase, L-arginine metabolism, GN 1107Arginine vasopressin, vascular smooth muscle cells

(abst), 799Aromatic L-amino acid decarboxylase 617Arterial occlusion, acute in ARF (abst) 215Astragalus Propinquns Schichk (abst) 505Atenolol, diabetic nephropathy, GFR (abst) 794ATP turnover (abst) 221Atrial natriuretic factor

down-regulation of salt excretion 673Prazosin, natriuresis 433receptors, responses in hypertrophy 75

Atrial natriuretic peptide (ANP)aortocaval fistula dogs 867displacement by urodilatin (abst) 234receptor, dietary fatty acid 265renal action 38:S-l27severe hyponatremia (abst) 1031

Autoreactive kidney-infiltrating T-cell clones 851Autosomal-dominant polycystic kidney disease

(ADPKD)acute cerebrovascular attacks (abst) 225blood pressure, kidney volume (abst) 211diagnosis with DNA probes (abst) 207gene testing (abst) 491genetic clinical study (abst) 202genetic counseling (abst) 207genetic diagnosis (abst) 210probability kidneys are different in 1199tubular renin 364urinary excretion, microalbuminuria, NAG (abst) 211

Azathioprineintolerance (abst) 205transplantation (abst) 216

Bacterial contamination, dialyzer membrane 61Bartter's syndrome (abst) 128713 integrins, glomerular epithelial cells 1099f32-microglobulin

elimination, HD (abst) 209removal in hemodiafiltration (abst) 1045turnover, dialysis 1434

Bezafibrate, lipoproteins, CRF, HD (abst) 199Bicarbonate dialysis

acetate-free biofiltration (abst) 501cardiac function and (abst) 233pre-dialytic hypotension (abst) 230vascular refilling (abst) 806venous system hemodynamics 718

Bicarbonate diuresis (abst) 503Biopsy

renal, detects CMV genome 1012renal, diabetic nephropathy (abst) 229renal percutaneous (abst) 494, 495tubulointerstitial lesions (abst) 494

Blood pressureACE inhibitors (abst) 220angiotensin, CRF 46elevation, saline infusion (abst) 508hemodialysis, CRF (abst) 215systemic, DM, Nephrology Forum 1470"white coat" hypertension (abst) 202

Blood transfusions, pretransplant (abst) 208Bone disease

adynamic, dialysis 38:S-62aluminum, advanced RF (abst) 213aluminum (abst) 212, 498aseptic necrosis (abst) 221

Bone marrowhemopoietic progenitor, dialysis (abst) 502rHuEPO, chronic insufficiency (abst) 206

Bone metabolism, renal insufficiency (abst) 499Bone mineral density

dialysis (abst) 805

transplantation (abst) 211, 808, 1048Bowman's capsule, leukocytes, anti-GBM disease

(abst) 1051Bradykinin-mediated effects of ACE inhibition,

Nephrology Forum 1020

C4 null phenotype, mutations, gene deletions (abst) .... 1032C4 RFLPs, membranous nephropathy 882C9 deficiency and IgA nephropathy 1253Calcineurin, cyclophilin-cyclosporine complex (abst) .... 802Calcitriol

hyperparathyroidism, HD (abst) 1041low-dose, dialysis 1191non-calcemic vit D analogs 38:S-43

Calciumintracellular, proximal tubules (abst) 797ketodiet in osteodystrophy 1217mass balance, calcium dialysate, HD (abst) 230metabolism, nephrotic syndrome 335metabolism, renal failure 38: S-37renal lithiasis (abst) 204

Calcium alginate, aluminum toxicity, HD (abst) 1045Calcium pump inhibitor, uremia 1328Calcium renal stones (abst) 803Calcium salts as phosphate binder, uremia 38:S-50Calorie restriction and remnant kidney 710Cancer, renal/pelvic (abst) 1042CAPD

acute pancreatitis (abst) 1287adequacy of 38:S-160autoimmune hypothyroidism (abst) 198complement system, children (abst) 797fluid kinetics, hypo-osmotic solution (abst) 797high molecular weight dialysate (abst) 503IL-l receptor antagonist, CRF 1419intraperitoneal neostigmine 1398lipoprotein level 424older patients at home (abst) 503pentoneal defenses, CCPD 947peritoneal function (abst) 205peritoneal inflammation 735peritonitis, fungal (abst) 200peritonitis, prostaglandins (abst) 798peritonitis, rates/risks 967staphylococcus aureus, rHuEPO (abst) 204urea kinetic model of evaluation (abst) 205

Captopriladriamycin, glomerulosclerosis (abst) 506diabetic nephropathy, albuminuria (abst) 794nifedipine, renal insufficiency 452renal artery stenosis (abst) 206, 1287

Cardiac hypertrophy in uremic rats 1079Cardiopulmonary recirculation modeling 1450

1524 Subject Index: Vol. 42

Carotid artery traction, natriuresis (abst) 234CD4 monoclonal antibody therapy (abst) 1033CD25 monoclonal antibody therapy (abst) 1033, 1046254Ag monoclonal antibody (abst) 1036Ceftizoxime, endotoxin influence (abst) 507Cell electrolytes, osmolytes in outer medulla 843Cell-type specific ganglioside of podocytes 624Cellular metabolites, renal injury 38:S-109Cerebrovascular attacks, ADPDK (abst) 225Children

asymptomatic syndrome (abst) 492complement system, CAPD (abst) 797Dengue fever nephritis (abst) 493glomerular disease (abst) 492HBV glomerulonephritis (abst) 493hemolytic uremic syndrome, IL-8 951lead poisoning, renal function 1226lupus nephritis (abst) 1043nephrotic syndrome (abst) 492, 493, 1038orthostatic proteinuria (abst) 493peritoneal equilibration test 102rhGH, calcium (abst) 1040TNF, glomerular disease (abst) 492transplantation 657, 1408transplantation (abst) 802uremia, growth hormone, Nephrology Forum 188urinary albumin excretion (abst) 1044

Chinese herbal medicine (abst) 498, 504, 505, 510Chondrocalcinosis, Bartter's syndrome (abst) 1287Chromogranin, glomerular peripolar cells (abst) 1049Chronic lymphocytic leukemia, GN 127Chronic renal failure

angiotensin effect on BP 46anti-platelet antibodies (abst) 497bacterial enzyme products (abst) 497bone disease (abst) 499calcium pump inhibitor 1328children, Nephrology Forum 188Chinese herbal medicine (abst) 498, 504hyperhomocysteinemia (abst) 229IL-l receptor antagonist 1419Liddle syndrome, nephrocalcinosis (abst) 233membrane ionic permeability 30002 consumption, PMNL 602oxygen radicals, antioxidants (abst) 496pathogenesis of anemia (abst) 796predicting 960prekallikrein-kallikrein system (abst) 496PUPA, Oenothera Biennis L in CRF (abst) 498rHuEPO, anemia, predialysis (abst) 498serum hyaluronic acid (abst) 496soluble TNF receptors 663T-lymphocyte transformation, IL-2 (abst) 497zinc, immunological functions (abst) 499

Chylomicron remnants in dialysis 1247Cimetidine, creatinine, GFR (abst) 793COL4A5 and Alport syndrome 83, 115, 1178, 1336Collagen types, Alport syndrome 115, 179Complement system

activation, OKT3, T-cells (abst) 796CAPD, children (abst) 797

Continuous arteriovenous hemodiafiltration (CAVHD)dialyzer geometry 448role of convection (abst) 209tobramycin clearance (abst) 209

Contrast medium, medullary sponge kidney (abst) 801Converting enzyme inhibition, proteinuria (abst) 795Cordyceps sinensis, ARF (abst) 495Cortisol as a mineralocorticoid 1297CR1 mRNA expression (abst) 228Creatinine clearance (abst) 1043Creatinine kinetics of evaluating CAPD (abst) 205Crescentic glomerulonephritis (abst) 489Crescentic nephritis (abst) 510Cryoglobulinemia, hepatitis virus C (abst) 803Cuprophane membranes, dialyzer geometry 442Cyclic AMP

G-protein stimulation, Na/H exchange 11ionic permeability, CRF 300

Cyclic peritoneal dialysis, CAPD 947Cyclophilin-cyclosporine complex (abst) 802Cyclophosphamide trials, idiopathic MGN (abst) 1032Cyclosporin A

diltiazem, transplantation (abst) 1047luteinizing hormone secretion (abst) 802proteinuria, adriamycin nephropathy (abst) 1283

Cyclosporinechronic liver disease (abst) 226corticoid-resistant nephrotic syndrome (abst) 802distal urinary acidification (abst) 225gingival hyperplasia (abst) 223glomerular thrombosis (abst) 1052graft survival, HLA typing 38:S-172HLA sensitization, allografts (abst) 220liver transplantation, ARF (abst) 227

nephrotoxicity 1

nephrotoxicity, P-170 glycoprotein (abst) 223proximal tubules (abst) 221

toxicity, endothelin antagonism 770toxicity (abst) 236transplantation (abst) 205, 216, 226

Cyprofloxacin, acute pyelonephritis (abst) 1040Cyst epithelial cells, NaC1 transport 308Cystic renal disease, acquired (abst) 198Cystitis, corinebacterium D2 group (abst) 226Cytokines

adenylate cyclase activity 559glomerular cell production (abst) 1037IgA nephropathy 341

Cytomegalovirusallografts, acyclovir (abst) 235DNA, IgA nephropathy, hematuria (abst) 488genome, renal biopsy detection 1012infection, allograft dysfunction (abst) 222transplantation (abst) 207, 216

DDAVP, hemodynamics, renin secretion (abst) 793ddl as HIV treatment (abst) 234DEAE-dextran, glomerular selectivity (abst) 1049Dengue fever nephritis, children (abst) 493Deoxyspergualin, anti-GBM GN (abst) 1034Dextran sulfate (abst) 1049Diabetes

dialysis, bone histomorphometry (abst) 214transplantation 38:S-193

Diabetes, non-insulin dependentglomerular volume (abst) 1053glycemic control, nephropathy 167

Diabetes insipidushydronephrosis, UT traumatic rupture (abst) 801

Subject Index: Vol. 42 1525

Diabetes mellitussystemic BP, Nephrology Forum 1470

Diabetic nephropathycaptopril, atenolol, GFR (abst) 794Chinese herbal medicine (abst) 504dyslipoproteinemia 1381enalapril, diet, microalbuminuria (abst) 208fibroblast Na/H antiport activity 1184glycemic control, NIDDM 167

hyperinsulinemia, glomerular hemodynamics 1160

prevention with glycosaminoglycans 285renal arteriosclerosis (abst) 1052renal biopsy (abst) 229thromboxane 937

Dialysisadequacy of, critical analysis 540adynamic bone disease 38:S-62amyloidosis and 38:S-78blood serotonin levels (abst) 1045bone mineral density (abst) 805

clearing chylomicron remnants 1247

dry weight measurement (abst) 796EPO, cytotoxic antibodies (abst) 218hepatitis C virus (abst) 204lipids, nutritional status (abst) 200polymorphonuclear cells, infection 38:S-91protease inhibitors, amyloidosis 915systemic amyloidosis (abst) 201

Dialysis disequilibrium syndrome (DDS) 161

Dialyzer geometryCAVHD 448hemodialysis 442

Dialyzer membranespermeability to pyrogens 61reused, anaphylactoid reactions 1232

Dietary fatty acid, ANP receptor 265Dietary protein

restriction, murine PKD 837vasopressin, hydration 1207

Dietary saltendothelin vasoconstrictive effect (abst) 508hypertension (abst) 1038

Digital intra-venous arteriography substraction (abst).... 214Diltiazem, transplantation, cyclosporin A (abst) 1047Dipyridamole trials, idiopathic MGN (abst) 1032Diuretic effect in outer medulla 843Dobutamine, renal metabolism, endotoxemia (abst) 796Donor organs

HLA typing (abst) 224, 809MLC-testing (abst) 807procurement (abst) 227

Dopamine, urodilatin, ischemic ARF 1153Dopexamine, renal metabolism, endotoxemia (abst) 796Doppler

allograft dysfunction evaluation (abst) 221renal artery stenosis, transplantation (abst) 201

Dry weight measurement, post-dialysis (abst) 796Dyslipoproteinemia, diabetic renal failure 1381

Eicosanoidsglomerular hemodynamics, IgA nephropathy 106superoxides, cell injury 69

Electrolytes, cellosmolytes, outer medulla 843

Enalaprilanemia, transplantation (abst) 206microalbuminuria, diet, IDDM (abst) 208

End-stage renal diseaseEPO, anemia, multiple myeloma (abst) 233HD, IgE associated (abst) 230hemodialysis, RBC (abst) 496prognosis with spinal cord injury (abst) 1031treatment (abst) 802, 1043tumor necrosis factor-a (abst) 497USRDS mortality tables 991

Endoglin, differentiation marker, macrophages (abst)... 1036Endothelial cells, allo specific antibodies (abst) 1284Endothelial-derived relaxing factor, obstruction 400Endothelin

antagonism, cyclosporine toxicity 770blood volume (abst) 508glomerular mesangial cells (abst) 509renal artery obstruction 632vasoconstriction, dietary salt (abst) 508

Endothelin- 1Na/H, Na/HCO3 18secretion, angiotensin II, MC 860

Endothelium, renal artery obstruction 632Endotoxemia, interstitial nephropathy (abst) 494Endotoxin

low-dose, preeclampsia (abst) 1283metabolic of ceftizoxime (abst) 507

Epidermal growth factor, MC production (abst) 1036Epithelial cells

adhesion, f integrins 1099aldosterone action 250culture, cell lines (abst) 236membrane fluidity, transport 825

Erythrocytosis post-transplant (abst) 219Erythropoietin

ACE inhibitors (abst) 1030anemia, ESRD, multiple myeloma (abst) 233anemia, transplantation (abst) 216arterial pressure (abst) 215cardiac effects (abst) 1041cell culture production (abst) 510glomerular hemostasis (abst) 804HD, CD34+ cells (abst) 216HD, hemoglobin, hematocrit (abst) 237hippuric acid (abst) 804hypobaric exposure (abst) 80402, hypoxic vasodilation 975relation to acidosis (abst) 804subcutaneous dosage (abst) 805uremia 407uremia (abst) 1031

Essential fatty acids, graft survival (abst) 1041

Essential hypertensionassociation with obesity (abst) 208insulin resistance (abst) 225metabolic tolerance to medical treatment (abst) 225

Excretory urogram, medullary sponge kidneys (abst) ... . 801Expert systems diagnose glomerular disease (abst) 1031Extraglomerular vascular immune deposits, IgA GN.... 1444

Fatty acidsdeficiency, graft survival (abst) 1041

dietary, ANP receptor 265Felodipine

during dopamine blockade (abst) 795

1526 Subject Index: Vol. 42

proximal tubule effect (abst) 1031

Fenoterol, hyperkalemia treatment (abst) 198

Fibrillary glomerulonephritis 1401

Fibroblast Na/H antiport activity 1184Fibronectin

mRNA splice variants (abst) 1037synthesis, TGF-/31, human MC (abst) 1032

Flow cytometry, renal tubular cells 997Focal segmental glomerulosclerosis (abst) 489, 799Fungal peritonitis in CAPD (abst) 200

G-protein stimulation, cyclic AMP 11

Ganoderma capense (abst) 504Gastrointestinal bleeding, periodic HD (abst) 201Gentamicin toxicity (abst) 232, 495Gingival hyperplasia and cyclosporine (abst) 223Globotriaosylceramide, TNF, IL-i (abst) 1286Glomerular basement membrane

anionic charge concentration (abst) 1050defect in Alport 179

permeability 25Glomerular cell types in rat kidney (abst) 1051Glomerular disease

children (abst) 492diagnosis, applied machine learning (abst) 1031

glucocorticoids 981immunologically mediated 38:S-123

Glomerular fibrinolytic activity, anti-GBM GN (abst)... 1034Glomerular filtration rate

creatinine, cimetidine (abst) 793

glycosilation products 875measurement, 99mTcDTPA, inulin 174modified plasma clearance 1006renal plasma flow (abst) 218

Glomerular hemodynamicshyperinsulinemia 1160starvation 567

Glomerular hypertrophy, post-uninephrectomy 136Glomerular peripolar cells (abst) 1049Glomerular thrombosis, cyclosporine (abst) 1052Glomerulogenesis, actin and PDGF 390Glomerulonephritis

CLL, related lymphomas 127complicated with hemoptysis (abst) 491crescentic (abst) 489fibrillary 1401glomerular anionic sites (abst) 491IgA, eicosanoid synthesis 106IgA, mesangial proliferative (abst) 223IgA deficiency, mesangial (abst) 219incidence, Spain (abst) 219L-arginine metabolism, arginase 1107leukotriene antagonists 38:S-l01MA histological analysis (abst) 199membrane attack complex (abst) 507mesangial, IL-i (abst) 507mesangial, IL-6 (abst) 800plasmin protease system 1462post-infectious, alcoholism (abst) 232proliferative lupus, cyclophosphamide (abst) 208T-cells, lymphokines, anti-GBM ON (abst) 1032

Glomerulopathyantiphospholipid antibodies (abst) 225thromboxane, diabetes 937

Glomerulosclerosisadriamycin, captopril (abst) 506focal segmental (abst) 489IL-l (abst) 1051

Glomerulusanti-DNA antibody binding 1363

rat kidney (abst) 1051Glucocorticoids

glomerular disease 981renal effect 1297

Glucosehomeostasis, Nephrology Forum 1266MC proliferation, TGF-/3 647transport, insulin-responsive 1086

Glycine metabolism, proximal tubular (abst) 1049

Glycine protective action 41, 775Glycosaminoglycans prevent nephropathy 285Glycosilation products, glomerular hyperfiltration 875Grafts

determining function (abst) 203embolization of with alcohol (abst) 202rejection, natural killer cells (abst) 224rejection, steroid/OKT3 therapy (abst) 223survival, cyclosporine, HLA typing 38:S-l72survival, essential fatty acids (abst) 1041

Growth hormonecalcium regulation, children (abst) 1040

Growth hormone, uremic children, Nephrology Forum .. 188

Guanidines, assay in plasma, urine (abst) 807

H-K-ATPase in renal medulla 10935-hydroxytryptamine receptors, noradrenaline (abst).... 12851 13-hydroxysteroid dehydrogenase, mammalian

nephron 56Hantavirus nephropathy (abst) 1285Hematuria, asymptomatic, children (abst) 492Hemodiafiltration (abst) 1044, 1045Hemodialysis

AgHBs, dialysis ultrafiltrate (abst) 232amyloidosis, a-2m (abst) 1040anaphylactoid reactions (abst) 218angiodysplasia, anemia (abst) 228antioxidant capacity, uremic erythrocytes (abst) 222antiphospholipid antibodies, CRF (abst) 211

f32-microglobulin elimination (abst) 209f32-microglobulin turnover 1434blood rheology (abst) 1046bone marrow hemopoietic progenitor (abst) 502calcitriol, hyperparathyroidism 1191

calcium alginate, aluminum hydroxide (abst) 1045calcium balance, calcium dialysate (abst) 230cardiopulmonary recirculation modeling 1450circadian BP rhythm, CRF (abst) 215compared with hemodiafiltration (abst) 1044control of hyperphosphatemia (abst) 807deformability of RBC (abst) 501dialysates, ventricular function (abst) 233dialyzer geometry 442, 448echocardiographic studies (abst) 216elevated serum aluminum (abst) 502endotoxic antibody (abst) 501Europe and U.S 38:S-l6gastrointestinal bleeding (abst) 201

hemodynamics, hemorrheology (abst) 500hemodynamics, venous system 718hepatitis B vaccination (abst) 212

Subject Index: Vol. 42 1527

hepatitis C virus (abst) 205, 207, 208, 209, 218high-efficiency (abst) 500high-flux dialysis, polysulfone membrane (abst) 500hollow-fiber, hemostasis (abst) 235hollow-fiber, hemostatic disturbances (abst) 807HTLV- 1 antibodies (abst) 238hypercalcemia (abst) 806hypotension, nitric oxide role 38:S-96IL-i, TNF 38:S-68IL-I receptor antagonist, CRF 1419IL-2 generation (abst) 199IL-6 production 320Legionella outbreak (abst) 219lipoprotein level 424lipoproteins, CRF, bezafibrate (abst) 199lipoproteins, CRF (abst) 200low dialysate flow rate (abst) 500low molecular weight heparin (abst) 217, 235measuring mass transfer (abst) 805nutritional assessment (abst) 201parathyroid hormone, erythropoiesis (abst) 502post-catheterism vein stenosis (abst) 235prevention of hepatitis B (abst) 501race, diabetes and death risk 38:S-22RBC, ESRD (abst) 496rHuEPO, anemia (abst) 501rHuEPO, heme metabolism (abst) 215rHuEPO, hemorrheological parameters (abst) 214single-needle, citrate anticoagulation (abst) 807technetium-labeled heparin (abst) 231urea distribution volume (abst) 217urea kinetic model (abst) 500vascular access (abst) 214, 232, 233vascular refilling during 1425

Hemodynamic dysfunction in DM, Nephrology Forum.. 1470Hemolytic uremic syndrome

IL-i, TNF (abst) 1286IL-8, neutrophils, children 951

Henoch-Schonlein purpura (abst) 490Heparin

glomerular proteinuria (abst) 1050low molecular weight, HD (abst) 217, 235technetium-labeled, HD (abst) 231

Hepatitis Bchronic, glomerular disease (abst) 229vaccination, HD (abst) 212

Hepatitis B virusglomerulonephritis, children (abst) 493pathogenesis (abst) 490

Hepatitis C virusantibody, home HD (abst) 207cryoglobulinemia type II (abst) 803dialysis (abst) 204hemodialysis (abst) 205, 208, 209, 218transplantation (abst) 226, 227

Herbal medicine (abst) 498, 504, 505, 510Heymann's nephritis (abst) 1034, 1051Hippuric acid, EPO response (abst) 804HIV infection

ddl treatment (abst) 234hemodialysis (abst) 238Ig binding to IgAN collagens 374renal disease (abst) 230

HLA typingallocating kidneys and (abst) 1285

donor kidneys (abst) 809graft survival, cyclosporine 38:S-172lymphocytes, cadaver donors (abst) 224sensitization, potential recipients 38: S-176

Hollow-fiber membraneshemostatic disturbances (abst) 235, 807reused, anaphylactoid reactions 1232

HSP7O mRNA transcription, regulation of 775Hyaluronic acid, serum, CRF (abst) 496Hypercalcemia

chronic hemodialysis (abst) 806transplantation (abst) 1048

Hypercalciuriaidiopathic, renal lithiasis (abst) 202insulin resistance, hypertension (abst) 225

prostaglandins (abst) 212

Hypercapnia, chronic (abst) 503

Hypercholesterolemia (abst) 506Hyperhomocysteinemia in CRF (abst) 229

Hyperinsulinemia, glomerular hemodynamics 1160Hyperkalemia, fenoterol treatment (abst) 198

Hyperlipidemiaglomerular injury (abst) 506

nephrotic syndrome 38:S-134Hyperparathyroidism

calcitriol, dialysis 1191

calcitriol, hemodialysis (abst) 1041calcitriol, non-calcemic vit D analogs 38:S-43hemodialysis, alfacalcidrol (abst) 1035hemodialysis, tumoral calcinosis (abst) 806low calcium dialysate (abst) 1041

MRI, subtraction gammagraphy (abst) 221

02, CRF, PMNL 602secondary uremic (abst) 208transplantation (abst) 211, 806, 808, 1048treatment, renal function (abst) 204

Hyperphosphatemiacalcium acetate as phosphate binder (abst) 807chronic respiratory alkalosis 727

HypertensionACTH, sodium chloride (abst) 1039dietary NaCI (abst) 1038exercise, pH recovery (abst) 1038insulin resistance, hypercalciuria (abst) 225insulin resistance, vascular risk factors (abst) 224monitoring "white coat" (abst) 202NaIH exchange 1355pregnancy, altered excretion rates (abst) 1039pregnancy, proteinuria (abst) 1038

Hypertransaminasemia, hepatitis C virus, HD (abst) 208Hypobaric exposure, EPO response (abst) 804Hypocalcemia, chronic respiratory alkalosis 727Hypocalciuria in kidney injury (abst) 216Hypomagnesemia, Bartter's syndrome (abst) 1287Hyponatremia, ANP (abst) 1031Hypophosphatemia, post-transplant (abst) 803Hypothyroidism, autoimmune in CAPD (abst) 198

Hypoxiaglycine protection mechanism 41protein kinase C, cell differentiation 1145

ICAM-l expression, effect on phagocytes (abst) 1037Idiopathic membranous glomerulonephritis

cyclophosphamide, warfarin, dipyridamole (abst) .... 1032predicting CRF 960

1528 Subject Index: Vol. 42

Idiopathic membranous nephropathyC4 RFLPs 882early stage (abst) 488

IgA deficiency, mesangial GN (abst) 219IgA glomerulonephritis

urinary platelet factor 4 (abst) 1051vascular immune deposits 1444

IgA nephritis (abst) 238IgA nephropathy

C9 deficient patients 1253clinical classification (abst) 488cytomegalovirus DNA, hematuria (abst) 488extracellular matrix in glomeruli (abst) 489extrarenal cytokines 341glomerular hemodynamics, eicosanoids 106HLA-DR genotyping (abst) 489Ig binding, HIV infection 374IL-2 receptor (abst) 198immunogenetic studies (abst) 1036lymphocyte function in tonsils (abst) 489mesangial deposit idiotypes (abst) 797mesangial proliferative GN (abst) 223neutrophil cytoplasmic antigen antibodies (abst) 490patterns of serum IgA (abst) 489role of complement (abst) 506

IgE, with ESRD (abst) 2301gM nephropathy, nephrotic syndrome (abst) 488Immunoadsorption (abst) 222Immunoglobulins, IgAN, HIV 374

Immunosuppressioncomparison study (abst) 1046herbal medicine study (abst) 504pituitary-testicular function (abst) 207transplantation (abst) 203

Impotence, erectile, treatment (abst) 226Injury

glomerular, diabetes 937glomerular, hyperlipidemia (abst) 506hypocalciuria, early stages (abst) 216

hypoxic 41ischemic, prostaglandin protection 1345ischemic, proximal tubule cell 896mesangial cell, monocyte adhesion 480mesangial cell, superoxides, TXB2 69post-ischemic regeneration, IGF-1 113renal, cellular metabolites 38:S-109renal cell 523renal hypoxia, free radicals, Na (abst) 1030tissue in lupus nephritis 755

Inositol transport, mesangial cells 33Insulin-like growth factor-i

binding protein 749regenerating kidney 1113

Insulin-responsive glucose transporter 1086Interleukin- I

glomerular sclerosis (abst) 1051induces verocytotoxin receptor (abst) 1286intrarenal (abst) 800mesangial cells, autocrine/paracrine (abst) 509mesangial cells, matrix synthesis (abst) 509mesangial cells (abst) 509mesangial proliferative GN (abst) 507production, herbal medicine (abst) 510TNF, hemodialysis 38:S-68

Interleukin-1 receptor antagonistCRF, dialysis 1419MCP-1 generation, MC 95

Interleukin-2CRF, T-lymphocytes (abst) 497generation during HD (abst) 199production in renal disease (abst) 199

Interleukin-2 receptoranti-CD25 monoclonal antibodies (abst) 794

idiopathic IgA nephropathy (abst) 198Interleukin-6

hemodialysis-related production 320mesangial cells (abst) 509mesangial glomerulonephritis (abst) 800TNF-a production, OKT3 (abst) 207

Interleukin-8, neutrophil activation, HUS 951

International Society of Nephrology, membershipsurvey 1295

Interstitial nephropathy, endotoxemia (abst) 494Intracavernosal vasoactive drugs (abst) 226Inulin

determination with microwave oven 459measuring GFR 174

Ionic permeability, CRF 300Iron

blood levels (abst) 204depletion, reactive oxygen species (abst) 1052

Ischemiaacute renal failure 610lowered osmoprotectants (abst) 1050nitroprusside 1153

PAF antagonists (abst) 203

prostaglandin protection 1345proximal tubule cell injury 896renal injury, prostaglandins 1345urodilatin, dopamine, ARF 1153

K-dependent acidifying ATPase, medulla 1093Ketodiet and Ca in osteodystrophy 1217Kt/V

hemodiafiltration, urea rebound (abst) 1045protein catabolic rate 38:S-32

L-arginine metabolism in GN 110715-Lipoxygenase products, leukotrienes, GN 38:S-l0lLaminin mRNA quantitation by PCR 764Lead nephropathy, children 1226Legionella (abst) 219Leiomyomatosis, Alport syndrome 1178Leukemia, chronic lymphocytic, GN 127Leukocytes, killing mesangial cells 1169Liddle syndrome (abst) 233Lipid peroxidation, Heymann's nephritis (abst) 1051

Lipidsnutritional status, dialysis (abst) 200, 214serum changes, uremia (abst) 496

Lipoproteinsdecreased receptor function, uremia 1238HD, CRF, bezafibrate (abst) 199hemodialysis, CRF (abst) 200level in CAPD, HD 424

Lithium reabsorption (abst) 1286Liver disease, cyclosporine induced (abst) 226Liver function, post-renal transplantation (abst) 808Liver growth factor, mesangial cells (abst) 210

Subject Index: Vol. 42 1529

Liver transplantation, cyclosporine, ARF (abst) 227Lomefloxacin, acute pyelonephritis (abst) 1043Loop diuretic effect in outer medulla 843Losartan, AT1 angiotensin II receptors (abst) 1048

Lupus glomerulonephritispathology indices 743proliferative, cyclophosphamide (abst) 208

Lupus nephritisanti-CD26 autoantibodies (abst) 1284anti-endothelial cell antibodies (abst) 1035children, adolescents (abst) 1043

cuyoxin pulse therapy (abst) 490GBM, anti-heparan sulfate, histones (abst) 793histological transformation (abst) 490kidney-infiltrating T-cell clones 851pregnancy (abst) 1042

reversibility in dialysis (abst) 501tissue injury 755treatment, prognosis (abst) 489tubular interstitial lesions (abst) 490type IV prognosis (abst) 489vascular cell adhesion molecule- 1 903

Lupus nephropathy, cytoplasmic antibodies (abst) 217

Luteinizing hormone, cyclosporine (abst) 802Lycium Barbarum Polysaccharide (abst) 505Lymphocytotoxic monoclonal autoantibodies (abst) .... 1032

Lymphokine production, T-cells, anti-GBM GN (abst).. 1032Lymphoma, CLL, glomerulonephritis 127Lysosomal iron

proximal tubular, remnant kidney (abst) 1053reactive oxygen species, puromycin nephrosis (abst). . 1052

Macrophage-colony stimulating factor, MC surface 279Magnesium concentration, erythrocytes (abst) 795Math model, cardiopulmonary recirculation 1450Medulla

angiotensin II receptors 1372loop diuretic effect 843

Medullary sponge kidneys, contrast medium (abst) 801Membrane fluidity, epithelial cells 825Membrane selection, muscle protein catabolism 38:S-86Membranous glomerulonephritis, herbal medicine

(abst) 504Membranous nephropathy

altered matrix 573antigen, immune deposits (abst) 488idiopathic (abst) 488prospective study (abst) 1043renin angiotensin, ANP (abst) 508

Mesangial antigen, monoclonal antibodies 700Mesangial cells

angiotensin, endothelin secretion 860antigen analysis, flow cytometry (abst) 509autocrine secretion of TGF-f3 1319endothelin effect (abst) 509heparin, extracellular matrix (abst) 798IL-l, TGF-13, matrix synthesis (abst) 509IL-i (abst) 509IL-i autocrine, paracrine (abst) 509IL-6 (abst) 509injury, monocyte adhesion 480injury, superoxide and TXB2 69inositol transport 33killing by leukocytes 1169liver growth factor (abst) 210

platelet activating factor 1309platelet interaction (abst) 210proliferation, TGF-f3, glucose 647secreted M-CSF 279take up apoptotic neutrophils 924TNF actions on (abst) 210TNF-a-induced PAI-l release 327

Methylprednisolone and glomerular diseases 981Microalbuminuria, ACE inhibition (abst) 200Microfilament disruption, ischemic proximal tubule

injury 896Microscopic polyarteritis (abst) 1039Mineralocorticoids 1297Modified plasma clearance, measuring GFR 1006Monoclonal antibodies

254Ag, complement C5b-9 deposits (abst) 1036histological analysis of GN (abst) 199HLA-B5 antigens (abst) 1047lymphocytotoxic autoantibody encoded (abst) 1032OKT3 procoagulant effect 1124recognizing novel mesangial antigen 700therapy, nephrotoxic nephritis (abst) 1033

Monoclonal gammapathy, post-transplant (abst) 231Monocyte adhesion, mesangial cell injury 480Monocyte chemotactic peptide- 1, IL- 1 ra, MC 95Multiple myeloma, EPO, anemia, ESRD (abst) 233Muscle protein catabolism, membrane selection 38:S-86Myeloperoxidase, renal perfusion (abst) 1284

Myocardial capillary density, uremia 1079

Na/H exchangeantiport activity, diabetic nephropathy 1184G-protein stimulation, cyclic AMP 11

hypertension 1355transporters, ET-1 18

Na-K-ATPase, ouabain sensitivity, CCD (abst) 800NAC1 transport, MDCK cyst epithelial cells 308Natriuresis

ANP, aortocaval fistula dogs 867bilateral carotid artery traction (abst) 234blunted volume expansion, adriamycin (abst) 234

Neostigmine, intraperitoneal, CAPD 1398Nephrectomy

graft embolization as alternative (abst) 202tubuloglomerular feedback (abst) 1049

Nephritiscrescentic, cell transfer (abst) 510hereditary, Nephrology Forum 783monoclonal antibody therapy (abst) 1033

Nephroblastoma (abst) 228Nephrocalcinosis (abst) 233, 1042Nephrology

advances in treatment 38:S-203clinical trials 1061

Nephropathyanalgesic, diagnosis of (abst) 1044analgesic and reflux (abst) 1041

cyclosporine, lymphoid irradiation (abst) 506immune complex, Paragonimiasis Westermani (abst)... 507interstitial, prostaglandin (abst) 510thin membrane (abst) 490

Nephrosis, ovarian hyperstimulation (abst) 800Nephrotic syndrome

acute renal failure (abst) 495adriamycin-induced, antioxidants, (abst) 507

1530 Si.bject Index: Vol. 42

apolipoproteins (abst) 1284Black African, histological (abst) 228children (abst) 492corticoid-resistant, cyclosporine (abst) 802edema, children (abst) 493glucocorticoid response (abst) 491hyperlipidemia 38:S-134idiopathic, leukocyte subsets (abst) 2241gM nephropathy (abst) 488lipoproteins, adriamycin (abst) 1283lymphocyte response, children (abst) 1038primary, fibrinolytic activity (abst) 491protein metabolism, herbal medicine (abst) 505sodium retention, glomerular changes (abst) 507sodium retention, renal dopamine (abst) 491tubular syndrome (abst) 212Vitamin D, calcium metabolism 335

Nephrotoxicitycyclosporine 1

cyclosporine, P-170 glycoprotein 223monoclonal antibody therapy (abst) 1033

Netilmicin, acute pyelonephritis (abst) 1040Neutral endopeptidase inhibition, oral SCH34826 (abst) . 1030

Neutrophilslysosomal enzymes (abst) 1037uremic, pH changes 690

Nifedipine, renal insufficiency 452Nitric oxide

hemodialysis, hypotension 38: S-96synthase of macula densa 1017

Nitroprusside, ischemic ARF 1153Nonamyloidotic fibrillary glomerulopathy (abst) 801Nutcracker phenomenon, children (abst) 493Nutritional status

calorie restriction, remnant kidney 710dialysis (abst) 200glomerular hemodynamics, starvation 567hemodialysis (abst) 201lipids, dialysis (abst) 214muscle protein catabolism 38:S-86pentoneal dialysis 38:S-l65

1,25 (OH)2-D3calcium reabsorption, renal lithiasis (abst) 204uremic hyperparathyroidism (abst) 208

1,25 Vit Dcalcium-phosphorous homeostasis, CRF (abst) 211

Obesity and essential hypertension (abst) 208Oenothera Biennis L in CRF (abst) 498OKT3 monoclonal antibody

dosage by body weight (abst) 808induces TNF-a, IL-6 production (abst) 207procoagulant effect 1124

Ontogeny of AADC in rat kidney 617Organ preservation solutions 38:S-197Orthostatic proteinuria

nutcracker phenomenon (abst) 493Osmolytes, cell electrolytes in outer medulla 843Osmoprotectants

human kidney, Na, urea levels (abst) 1030lowered by ischemia (abst) 1050urinary excretion (abst) 1035

Osteodystrophy, renal99InTCMDP bone scan (abst) 498aluminum (abst) 498

ketodiet, calcium, Vit D 1217

pathological analysis (abst) 499PTH, l,25(OH)2D3 (abst) 499

Ovarian hyperstimulation syndrome, nephrosis (abst).... 800Oxalosis, transplantation, children 1408

Oxygen consumption, hyperparathyroidism 602Oxygen radicals

increased, eicosanoids, injury 69injury, renal hypoxia, Na (abst) 1030

4-pentenoate, renal effects 586

Pancreatitis, CAPD (abst) 1287Panel reactive cytotoxic antibodies, EPO (abst) 218Paragonimiasis Westermani, nephropathy (abst) 507Parathyroid hormone

hemodialysis, erythropoiesis (abst) 502stimulation, phosphate loading (abst) 1050suppression on dialysis (abst) 1045

Parathyroidectomy, graft dysfunction (abst) 1048Pelvic cancer (abst) 1042

Peptidesintestinal, Na uptake (abst) 1050

plasma, uninephrectomy (abst) 236Percutaneous transluminal angioplasty

renal artery stenosis (abst) 217Percutaneous transvenous angioplasty

vascular access stenosis 1390

Perindoprilat, hypoxemia (abst) 799Peritoneal catheters, Moncriefs technique (abst) 205Peritoneal dialysis

adequacy (abst) 214bone marrow hemopoiesis (abst) 502catheter obstruction (abst) 503intermittent whole-day, CRF (abst) 503nutritional aspects 38:S-165overview 38:S-148peritonitis (abst) 503, 1046solutions, 1% amino acid (abst) 803solutions, improved 38:S-153

Peritoneal equilibration test in children 102Peritoneal inflammation, CAPD 735Peritonitis

bacterial, PD (abst) 503CCPD, CAPD 947fungal, CAPD (abst) 200intestinal failure, PD (abst) 1046prostaglandins, CAPD (abst) 798rates/risks, CAPD 967

Phosphateloading, parathyroid stimulation (abst) 1050transport, kidney endosomes 1070

Phospholipase C-a from porcine kidney 888Pituitary-testicular function (abst) 207Plasmapheresis, acute vascular rejection (abst) 222Plasmin protease system in GN 1462Plasminogen activator inhibitor-l, TNF-a, MC 327Platelet activating factor

antagonist, warm ischemia time (abst) 203porins stimulate PAF, MC 1309

Platelet-derived growth factor, glomerulogenesis 390Platelet factor 4, IgA GN (abst) 1051Platelets

function, EPO, uremia 668mesangial cell interaction (abst) 210

Plumbism after chelation, childhood 1226

Subject Index: Vol. 42 1531

Podocytescell-type specific ganglioside 624focal segmental glomeruloscierosis (abst) 799structure, post-uninephrectomy 148

Polyacrylonitrile membrane (abst) 238Polyamide membrane (abst) 806Polyarteritis, microscopic (abst) 1039Polycystic disease

dietary protein restriction 837renal histology 1259

Polymorphonuclear leukocytesCRF, 02 consumption 602dialysis 38:S-91

Polyunsaturated fatty acids, CRF (abst) 498Potassium reabsorption, rubidium 272Prazosin, ANF response 433Pre-term babies, nephrocalcinosis (abst) 1042Prednisone, transplantation (abst) 216Preeclampsia

glomerular changes (abst) 1052low-dose endotoxin (abst) 1283

Pregnancyhypertension, excretion rates (abst) 1039lupus nephritis (abst) 1042proteinuria, hypertension (abst) 1038proteinuria, renal function (abst) 795

Prekallikrein-kallikrein system, CRF (abst) 496Primary hyperoxaluria type 1 1408Primary vasculitis, renal involvement (abst) 490Procoagulant effect of OKT3 1124

Prostaglandin E2angiotensin II, stenotic kidney 417excretion, hypercalciuria (abst) 212

Prostaglandinsinterstitial nephropathy (abst) 510peritonitis, CAPD (abst) 798renal cytoprotection 1345

Protease inhibitors, dialysis amyloidosis 915Protein, cytoskeletal, integrins, ECM (abst) 793Protein catabolism

membrane selection 38: S-86rate and Kt/V 38:S-32

Protein kinase C, hypoxia 1145Protein meal and vasopressin 1207Protein metabolism

effect of ammonia 595effects of ketoacids (abst) 497

Protein transport, transperitoneal 1412Proteinuria

analgesic and reflux nephropathy (abst) 1041CEI, mesangial expansion (abst) 795cyclosporin A, adriamycin nephropathy (abst) 1283decrease during ACE inhibition (abst) 1285glomerular, heparin sulfate (abst) 1050pregnancy, hypertension (abst) 1038pregnancy, renal function (abst) 795

Proximal tubular epithelial cells 383, 1130Proximal tubule

cyclosporine (abst) 221felodipine effect (abst) 1031glycine metabolism (abst) 1049

Prurigo nodularis, aluminum toxicity (abst) 1044Puromycin, nephrosis (abst) 800, 1052Pyelitis, encrusted, corinebacterium D2 group,

transplantation (abst) 226

Pyelonephritis, acute (abst) 1040, 1043

Reactive oxygen species (abst) 1052Recombinant human erythropoietin

anemia, predialysis CRF (abst) 498bone marrow, chronic insufficiency (abst) 206CAPD, staphylococcus aureus (abst) 204dosage, hemodialysis (abst) 805, 1046uremia, platelet function 668uremia, primary hemostasia (abst) 220uremic anemia 38:S-l42

Red blood cell membrane, calcium pump, CRF 1328Reflux nephropathy (abst) 493Regenerating kidney and IGF- 1 1113Renal angiomyolipoma, tuberous sclerosis (abst) 801Renal artery stenosis

captopril, renal scintigraphy (abst) 1287captopnl renography (abst) 206percutaneous transluminal angioplasty (abst) 217transplantation, Doppler (abst) 201transplantation (abst) 1286

Renal cancer (abst) 1042Renal cortex, ET-1, Na/H, NaJHCO3 18Renal disease

acquired cystic (abst) 198

arresting 38:S-1 14

epidemiology, Spain (abst) 213HIV infection (abst) 230ischemia, ARF 610renal reserve pattern (abst) 1042sex hormone level (abst) 492

Renal expression of GLUT4 1086Renal failure

calcium metabolism 38:S-37calcium-related changes (abst) 1040captopril, nifedipine 452experimental, bacterial enzymes (abst) 497renal histology in PKD 1259

Renal functionchildhood lead poisoning 1226de-electrolyte water clearance (abst) 494endothelium, endothelin in obstruction 632handling of silicon 957oxidation patterns (abst) 210pregnancy (abst) 795

Renal growth factor, post-uninephrectomy (abst) 199Renal hypertrophy

ANF receptors 75compensatory (abst) 1035

Renal lithiasis1,25(OH)2 D3, calcium reabsorption (abst) 204idiopathic hypercalciuria, metabolism (abst) 202

Renal prepro-EGF, obstruction 89Renal replacement therapy, death rates 38:S-4Renin

autoradiographic localization 639tubular in ADPKD 364vasopressin agonist DDAVP, hemodynamics (abst).... 793

Renin angiotensin system, nephropathy, ANP (abst) 508Renotropin (abst) 510Respiratory alkalosis, mineral metabolism 727Reverse urea effect in DDS 161Rheum officinal(e) (abst) 504, 505, 510Rheumatoid arthritis, renal function (abst) 1040Rhubarb, therapeutic effect (abst) 498

1532 Subject Index: Vol. 42

Rubidium, potassium reabsorption 272Rufioxacin, impaired renal function (abst) 1042

Salt excretion down-regulation by ANF 673SchOnlein-Henoch glomerulonephritis 341Serotonin, dialytic therapy (abst) 1045Sex hormone level in renal disease (abst) 492Shenshuai No 1. (abst) 498Signalling disorders, transmembrane, cyclosporineSilicon, renal handling of 957Single-needle hemodialysis, citrate (abst) 807Skeletal muscle metabolism, uremia (abst) 1031, 1049Sodium

dietary, anti-hypertensives, renal effect 354retention, nephrotic syndrome, glomerular changes

(abst) 507Sodium chloride, ACTH hypertension (abst) 1039Sodium-dependent phosphate transport 1070Spinal cord injury, prognosis with ESRD (abst) 1031Staphylococcus aureus, CAPD, rHuEPO (abst) 204Superoxide dismutase, renal failure (abst) 222Sympathetic nervous system, ANF, natriuresis 433Systemic lupus erythematosus

C8, C9, membrane attack complex (abst) 1037drug therapy study (abst) 801GN pathogenesis 1363intraglomerular thrombi (abst) 233membrane antigens (abst) 1038

99mTc..DTpA measuring GFR 174T-cells

allograft rejection (abst) 1047clones, lupus nephritis 851lymphokine production, anti-GBM GN (abst) 1032uremic serum 681

Tamm-Horsfall expressionchronic active hepatitis (abst) 494ureteral obstruction 89

Testicular-pituitary function (abst) 207Thin membrane nephropathy (abst) 490Thrombocytopenia, ARF, hemodiafiltration (abst) 1044Thrombomodulin glomerular activity (abst) 231Thrombotic microangiopathy (abst) 229Thromboxane, glomerulopathy, diabetes 937Thyroid function, age, CRF, dialysis (abst) 237Transforming growth factor-fl

fibronectin synthesis (abst) 1032mesangial cells 1319mesangial cells, glucose 647mesangial proliferative GN (abst) 507production, rat MC (abst) 1033

Transmembrane signalling disorders 1

Transperitoneal protein transport 1412Transplantation

antilymphocyte globulins 38: S- 188

azathioprine, cyclosporine, prednisone (abst) 216blood transfusions, prior (abst) 208bone mineral density (abst) 211, 1048bone necrosis, aseptic (abst) 221bone redistribution (abst) 808children 657children, growth potential (abst) 802cross match techniques (abst) 237cyclosporin A, diltiazem (abst) 1047cyclosporine, azathioprine (abst) 205cyclosporine (abst) 226

cytomegalovirus (abst) 207, 216diabetic patients 38:S-193enalapril, anemia (abst) 206erectile impotence treatment (abst) 226erythrocytosis (abst) 219erythropoietin-deficient anemia (abst) 216glomerular hyperfiltration (abst) 809hepatitis B prevention (abst) 501hepatitis C virus (abst) 226, 227HLA-sensitization 38:S-l76HLA typing, allocating kidneys (abst) 1285

hyperparathyroidism (abst) 211, 806, 808, 1048immunocytology, urinary sediments (abst) 794immunosuppression, pituitary, testes (abst) 207immunosuppression (abst) 203, 1046liver function after (abst) 808MLC-te sting (abst) 807monoclonal gammapathy after (abst) 231

OKT3 therapy (abst) 223, 228parathyroidectomy (abst) 1048patient profiles, death rates 38:S-4PH 1 children 1408prognosis after failed dialysis (abst) 803

pyelitis, cystitis (abst) 226renal artery stenosis (abst) 201, 1286triple drug protocol (abst) 220

Trypterigium wilfodii (abst) 504, 505Tuberous sclerosis, renal angiomyolipoma (abst) 801Tubular cells

Chinese herbal medicine (abst) 505flow cytometry 997

Tubuloglomerular feedback, post-nephrectomy (abst)... 1049Tubulointerstitial lesions in renal biopsy (abst) 494Tumor necrosis factor

IL-l, hemodialysis 38:S-68induces verocytotoxin receptor (abst) 1286inhibition, herbal medicine (abst) 510mesangial cells (abst) 210OKT3 procoagulant effect 1124

Tumor necrosis factor-aESRD (abst) 497PAl-i release, mesangial cells 327production, IL-6, OKT3 (abst) 207proximal tubular epithelial cell production 383

Tumor necrosis factor receptorsoluble in CRF 663

Tumoral calcinosis (abst) 806

Ultrafiltrationvascular refilling during 1425venous system hemodynamics 718

Uninephrectomyglomerular hypertrophy 136plasma concentration of peptides (abst) 236podocyte structure changes 148renal growth factor (abst) 199urolithiasis 292

U.S. Renal Data System, ESRD mortality tables 991Urea kinetic modeling

CAPD (abst) 205hemodialysis 1450hemodialysis (abst) 500

Uremiaanemia, EPO 38:S-142, 975calcium pump inhibitor 1328

Subject index: Vol. 42 1533

calcium salts as phosphate binder 38:S-50EPO, platelet function 668erythrocyte membrane transport (abst) 496erythropoietin response 407LDL receptor function, mRNA levels 1238myocardial capillary density 1079plasma MDA, erythrocyte MDA, SOD (abst) 495serum and T-cells 681serum lipids (abst) 496skeletal muscle metabolism (abst) 1031, 1049soluble TNF receptor 663

Ureteral obstructionendothelin, endothelium 632renal prepro-EGF, gene expression 89unilateral and EDRF 400

Urinary sediments, transplant rejection (abst) 794Urinary tract, traumatic rupture (abst) 801Urodilatin

displacing labeled ANP (abst) 234dopamine, ischemic ARF 1153

Urolithiasis, uninephrectomy 292

Vascular access stenosis, PTVA 1390

Vascular cell adhesion molecule- 1gene expression (abst) 1035

lupus nephritis 903Vascular permeability factor, human kidney 1457Vascular refilling, HD, ultrafiltration 1425Vascular smooth muscle cells (abst) 799Vasopressin

agonist, hemodynamics, renin (abst) 793protein meal 1207

Ventricular functiondiffering HD dialysates (abst) 233vitamin D-3 (abst) 198

Verocytotoxin receptor, induced (abst) 1286Vitamin D

metabolism, nephrotic syndrome 335ventricular function (abst) 198

Vitamin E and herbal medicine (abst) 505

Warfarin trials, idiopathic MGN (abst) 1032

Wegener's granulomatosis (abst) 213"White coat" hypertension (abst) 202Wilms' tumor (abst) 228